[ZBH Q2 2026 Earnings Call] Zimmer Biomet Beats and Raises as Hip, Tech Sales Surge; U.S. Technology Revenue Jumps 53% — BigGo Finance
Zimmer Biomet (ZBH) reported Q2 2026 net sales of $2.177B (+4.8%) and GAAP diluted EPS of $1.03 (+33.8%), with technology sales up 53% in the U.S. Hip sales grew about 6% and knees were nearly flat. The company raised 2026 organic revenue growth to 2.25%–3.25% and adjusted EPS to $8.47–$8.59, and plans up to $1B buybacks.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised full-year guidance ranges, the increased share repurchase authorization, and the segment-level acceleration in U.S. technology sales.
Market read
This is a direct earnings-and-guidance update with specific numeric ranges and capital return details, likely driving near-term repricing.
What to watch
The sales-force restructuring is still mid-transition (full specialized structure targeted for end of 2027), so execution risk remains even with multi-year-low attrition.
Background
Zimmer Biomet is in the middle of a sales-force restructuring and is emphasizing a product pipeline across hips, robotics/navigation, and S.E.T. (sports, extremities, trauma).
Ticker impact
Zimmer Biomet beat Q2 results and raised 2026 organic revenue growth to 2.25% to 3.25%, plus adjusted EPS to $8.47 to $8.59.
Likely positive bias for the stock into the next session as traders reprice 2026 earnings power and capital return.
The article provides specific beat-and-raise guidance ranges, EPS uplift, and an increased $1B buyback plan, which are direct valuation inputs.
Market effects
Supports the view that orthopedic medtech demand is stabilizing, with robotics and navigation driving outperformance versus knees softness.
U.S. technology growth (53%) is a key driver, while international knees weakness highlights regional divergence.
Japan iodine-coated hip launch described as demand exceeding supply, suggesting localized supply constraints could persist.
Counterpoint
Knees are essentially flat and margins are pressured (gross and operating margin down), so the raise may rely heavily on technology and hip mix.
Key entities
- public_companyZimmer Biomet
Reported Q2 beat-and-raise results, highlighted hip and U.S. technology growth, and lifted 2026 guidance plus buybacks.
- executiveIván Tornos
CEO who attributed results to hip momentum, technology rep additions, and the ongoing sales-force transformation.
- executivePaul Stellato
Interim CFO referenced as supporting the transition while the company searches for a permanent CFO.
